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Abstract
Previous studies suggest that protective immunity against Schistosoma haematobium is primarily stimulated by antigens
from dying worms. Praziquantel treatment kills adult worms, boosting antigen exposure and protective antibody levels.
Current schistosomiasis control efforts use repeated mass drug administration (MDA) of praziquantel to reduce morbidity,
and may also reduce transmission. The long-term impact of MDA upon protective immunity, and subsequent effects on
infection dynamics, are not known. A stochastic individual-based model describing levels of S. haematobium worm burden,
egg output and protective parasite-specific antibody, which has previously been fitted to cross-sectional and short-term
post-treatment egg count and antibody patterns, was used to predict dynamics of measured egg output and antibody
during and after a 5-year MDA campaign. Different treatment schedules based on current World Health Organisation
recommendations as well as different assumptions about reductions in transmission were investigated. We found that
antibody levels were initially boosted by MDA, but declined below pre-intervention levels during or after MDA if protective
immunity was short-lived. Following cessation of MDA, our models predicted that measured egg counts could sometimes
overshoot pre-intervention levels, even if MDA had had no effect on transmission. With no reduction in transmission, this
overshoot occurred if protective immunity was short-lived. This implies that disease burden may temporarily increase
following discontinuation of treatment, even in the absence of any reduction in the overall transmission rate. If MDA was
additionally assumed to reduce transmission, a larger overshoot was seen across a wide range of parameter combinations,
including those with longer-lived protective immunity. MDA may reduce population levels of immunity to urogenital
schistosomiasis in the long-term (3–10 years), particularly if transmission is reduced. If MDA is stopped while S.
haematobium is still being transmitted, large rebounds (up to a doubling) in egg counts could occur.
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Introduction
Urogenital schistosomiasis (caused by the blood fluke Schisto-
soma haematobium) remains a prevalent tropical disease, infecting
over 100 million people in sub-Saharan Africa [1,2]. Recent
control efforts have focussed upon mass drug administration
(MDA) using the antihelminthic drug praziquantel [3,4], with the
principal aim of reducing morbidity, although MDA can
significantly reduce both population infection levels [5,6] and
transmission rates [5,7]. To maintain low infection levels
treatments must be repeatedly administered for an indefinite time
period [8,9].
MDA reduces infection levels directly through killing worms,
and indirectly through reducing transmission. Acquired immunity
enhances treatment efficacy, and influences subsequent infection
dynamics [10]. Previous modelling work, which assumed protec-
tive immunity was stimulated by live worms, suggested that
repeated population-level treatment would disrupt the develop-
ment of acquired immunity by removing the antigenic stimulus
[10,11]; if treatment ceased, then under some circumstances,
infection levels could ‘overshoot’ to exceed pre-treatment levels
[10].
Protective immunity to schistosomes appears to develop slowly,
with children in endemic areas experiencing repeated re-infection
while adults experience much lower levels of infection, even with
high exposure [12,13]. Infection intensity peaks at an earlier age in
areas with more intense transmission [14], and this is mirrored by
immune responses associated with protection [15], suggesting that
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protective immunity is related to cumulative exposure to infection
rather than age-related physiological factors. Earlier studies have
shown that age-related changes in reinfection rates are explained
by protective antibody levels [16], and that the development of
resistance is dependent upon exposure history [17]. Several studies
have demonstrated that praziquantel treatment boosts schisto-
some-specific antibody responses to S. mansoni and S. haemato-
bium [18–20], and accelerates isotypic changes which occur more
gradually with age [21,22]. Praziquantel kills adult worms,
enhancing serological recognition of S. haematobium antigens
[23]. Increased exposure to antigens released from dying worms is
thought to be responsible for stimulating these immunological
changes following praziquantel treatment. Several of the responses
boosted by praziquantel treatment, including IgE, IgG1, and
cytokines IL-4 and IL-5, have been associated with protection
against re-infection in other studies [16,20,24,25], and some
studies have shown that responses boosted by treatment are
associated with protection against re-infection in the same
population [26,27], suggesting that treatment enhances protective
immunity.
Recent mathematical modelling for S. haematobium showed
that post-treatment boosts in antibody responses associated with
protection are most consistent with protective antibody being
stimulated by dying worms and reducing worm fecundity [28].
This study suggested that if protective antibody were mainly
stimulated by antigens from other life stages (including cercariae,
live worms, or eggs) then a boost in antibody would not be seen
following treatment [28]. No models have previously looked at
long-term effects of MDA upon the dynamics of protective
immunity and measured egg output when such immunity is
stimulated by dying (rather than live) worms. While treatment is
expected to increase antigenic exposure and boost protective
immune responses in the short term through worm killing, a
period of reduced exposure to dying worms will follow the initial
reduction in worm burden since treatment causes worms to die
sooner than they naturally would. Exposure will be further
reduced if population-wide treatment reduces transmission rates,
decreasing re-infection. The long-term implications of mass
treatment for the development of protective immunity are not
fully clear [29].
Here, using a model with protective immunity stimulated by
antigens released from dying S. haematobium worms, we assess the
expected impact of MDA upon the development of acquired
immunity, and upon measured egg output, both during and after a
mass treatment campaign.
Methods
The model
We used a stochastic individual-based model which describes
changes in worm burden, egg output and a protective antibody
response with age for people living in an area with endemic
schistosome infection. This model has been fully described
previously [28]. Briefly, the model tracks the number of worms
an individual harbours between their birth and 34 years of age.
Individuals acquire new worms through contact with water
containing infective larvae. As suggested by field studies, rates of
water contact change with age [30] and vary between individuals
[31].The number of cercariae acquired per water contact is
independent of population infection levels and remains constant
over time (unless reduced transmission is assumed during MDA).
Note that transmission of parasites between humans and snail
intermediate hosts is not explicitly modelled. Acquired cercariae
develop into adult worms (with approximately Gaussian-distribut-
ed survival, following earlier modelling studies [32]), which
produce eggs. The number of eggs within the host is assumed to
be proportional to current worm burden but reduced by protective
antibody. It is also assumed that egg output per worm is constant
regardless of worm age. Measured egg output is calculated as the
average of three ‘samples’ drawn from a negative binomial
distribution around the number of within-host eggs. The
protective antibody response is relatively long-lived (decay rate
of 0.008–0.8 year21, equivalent to a half-life of 10 months–87
years), as suggested by earlier model fitting [28]; no direct
estimates are available for the longevity of protective immunity
against schistosome parasites in humans, but these estimates fall
between the decay rates estimated for antibody responses to other
pathogens [33], and for memory B cells [34]. Protective antibody
is stimulated by antigens from dying worms and reduces worm
fecundity, as suggested by previous comparison of model output
with field data [28], and as demonstrated for the leading
schistosome vaccine candidate, a 28 kDa glutathione S-transferase
[35]. Most of the models used here include an ‘antigen threshold’,
a level of cumulative antigen exposure which must be exceeded
before a protective antibody response is mounted, as suggested by
previous model fitting, but we include models without an antigen
threshold which have also been found to fit the data [28].
Model parameterization and fitting
In earlier work, this model was parameterised using data from
studies in Zimbabwe and elsewhere, and fitted to population data
on pre- and post-treatment S. haematobium egg counts and specific
antibody responses from several rural sites in Zimbabwe with
endemic infection [28]. A grid-search of parameter space was
performed to identify parameter combinations which were
consistent with field data, varying the following parameters
simultaneously: mean population infection rate, worm life span,
antibody strength, immune response decay rate, and antigen
threshold level. This grid-search was repeated, varying each of the
following parameters separately: aggregation of contacts, rate of
Author Summary
Urogenital schistosomiasis, caused by schistosome blood
flukes, infects more than 100 million people in sub-Saharan
Africa. Current control efforts involve regularly treating all
school-aged children with the drug praziquantel, which
kills schistosome worms. Earlier work by our group
suggests that protective immunity against schistosomes
is mainly stimulated by dying worms, and that in the short
term, praziquantel treatment boosts immunity through
killing worms. The longer-term impact upon the develop-
ment of protective immunity is unknown. In this paper, we
used a mathematical model which was able to replicate
short-term patterns of infection and antibody to predict
the long-term changes in antibody and infection levels
that would occur during and after a 5-year treatment
programme. We found that the longevity of protective
immunity was particularly influential. Short-lived protec-
tive immunity was associated with levels of protective
antibody declining below pre-treatment levels in the long
term, and also with an increase in measured infection
levels (eggs in urine) to peak above pre-treatment levels
after the treatment programme finished. Antibody de-
clines and infection peaks post-treatment were also
predicted if treatment programmes reduced schistosome
transmission. These results highlight the possible negative
consequences of ceasing mass treatment programmes
once they have commenced.
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changing contact rate, aggregation of acquired cercariae, number
of eggs per worm, and aggregation of egg output. Parameter
combinations from all of these grid-searches which were able to
reproduce cross-sectional egg output and antibody patterns and
short-term post-treatment egg output and antibody dynamics were
used in the current analysis to estimate the long-term impact of
treatment.
Population structure
A population of 175 individuals was simulated, with 5
individuals in each yearly age group from 1 to 34 years old at
the time of the baseline survey. Individuals were simulated up to
their respective ages before the initial baseline egg count and
antibody levels were recorded and the first round of treatment
applied. Individuals were then simulated for a further 15 years
after this initial survey, during and after MDA (see next section for
treatment schedules). When individuals reached the age of 34, they
were replaced by 1 day old infants with no worms or antibody, to
maintain a constant population size.
Treatment schedules
Six treatment schedules were used which vary treatment
frequency, target population, coverage and reduction in transmis-
sion (table 1). For the standard treatment schedule (schedule 1),
treatment was given to school-aged children, defined as those aged
6–15 years old, as recommended by the WHO and implemented
by the Schistosomiasis Control Initiative (SCI) [3,4]. Treatment
was applied annually for five years (five treatments in total).
Annual treatment is advised for, and used in, high-prevalence
communities [3,4]. In the standard treatment schedule, coverage
was assumed to be 75%, in line with WHO targets and achieved
coverage in several countries [3,36,37], and it was assumed that
treatment did not affect transmission.
In each of the other treatment schedules, one parameter was
changed from the standard schedule (table 1). In schedule 2,
biennial treatment (i.e. treatment every two years) was given over a
five year period (three treatments in total). Biennial treatment is
advised for, and used in, areas with moderate prevalence [3,4].
Schedule 3 had 90% treatment coverage (as achieved in some
countries [38,39]). In schedule 4, the whole population over the
age of 5 was treated, as recommended and implemented for high
risk populations [3,4]. In schedules 5 and 6, it was assumed that
treatment reduced transmission by 100% or 50% respectively. For
simplicity, treatment was assumed to reduce transmission as a step
change to a fixed level, from the day after the first treatment up
until one year after the final treatment, when transmission
returned to its original level.
For all treatment schedules (1–6), treatment was applied over a
five year period and each treatment was applied the day after egg
counts and antibody levels were recorded. Treatment was applied
randomly across the eligible population at the required coverage
level (75% or 90%) at each round of treatment, meaning that an
individual’s chance of being treated in each round was indepen-
dent of whether they had been treated in previous rounds.
Treatment was assumed to be given independently of worm
burden or egg output, in line with the usual MDA strategy of
giving treatment to all school-aged children [3]. For all schedules,
a treatment efficacy of 90% was assumed (90% of worms were
killed), which gave reductions in egg output of 87–98%, in line
with field studies [40].
Analysis
For each parameter set, 200 repeat simulations of the whole
population were run, and mean levels of egg output and antibody
for the whole population aged 6–34 years old were calculated pre-
treatment and at yearly intervals during and after the simulated
treatment regime, averaged over the 200 repeat simulations. This
age range was used in order to capture the changes in egg counts
and antibody levels in treated individuals as they aged over the
long follow-up period. Egg output and antibody dynamics were
studied to see how quickly they returned to pre-treatment levels.
The conditions (parameter values or treatment schedules) under
which protective antibody levels fell below pre-treatment levels or
egg counts overshot pre-treatment levels were identified.
Results
Standard treatment schedule (schedule 1)
Importance of immune decay rate and worm life
span. We found that protective antibody dynamics were mainly
determined by immune decay rate and worm life span – this is
illustrated with selected parameter sets which reflect the general
patterns seen (exceptions are noted in the section on overshoots in
egg output). Figure 1 shows how levels of antibody and egg output
varied with immune decay rate for the same worm life span (6.5
years). Protective antibody always increased after the initial round
of treatment, with the greatest relative boost, and greatest
subsequent drop, seen with the most rapid immune decay rate
(figure 1a; note that this figure shows relative changes in antibody
levels. Actual antibody levels are shown for comparison in
supplementary figure S1a). With rapid immune decay, antibody
levels peaked one year after treatment began and declined during
subsequent treatment rounds whereas models with slower immune
decay saw progressive increases in antibody levels over five years of
treatment (figure 1a). For most parameter sets, little difference was
Table 1. Treatment schedules used.
Schedule description Treatment frequency Target population Treatment coverage Effect on transmission
1 Standard Annual Schoolchildren (6–15 years old) 75% None
2 Biennial Biennial Schoolchildren (6–15 years old) 75% None
3 90% coverage Annual Schoolchildren (6–15 years old) 90% None
4 Treat all aged 6–34 years old Annual Schoolchildren and adults
(6–34 years old)
75% None
5 100% transmission reduction Annual Schoolchildren (6–15 years old) 75% 100% reduction
6 50% transmission reduction Annual Schoolchildren (6–15 years old) 75% 50% reduction
doi:10.1371/journal.pntd.0003059.t001
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seen in egg output for different immune decay rates (figure 1b,
figure S1b). Levels of egg output fell and then plateaued over the
five rounds of treatment, and then returned to pre-treatment levels
after treatment ceased, over a similar timescale for all immune
decay rates (figure 1b).
Figure 2 shows how levels of antibody and egg output varied
with parasite life span for the same level of immune decay (0.8
year21). Models with a longer parasite life span showed both a
higher boost and a more substantial drop in antibody levels than
those with shorter parasite life span (figure 2a; similar results are
seen for less rapid immune decay, figure S2a,c). Antibody levels
dropped below pre-treatment levels before the fifth round of
treatment if immune decay was rapid (0.8 year21) and worm life
span was short (3 years) (figure 2a). Egg output levels were reduced
to a lesser extent, and returned to pre-treatment levels earlier, with
progressively shorter worm life span (figure 2b, figure S2b,d).
Overshoots in egg output. For the standard treatment
schedule (which assumes no reduction in transmission during
MDA), some parameter combinations were identified which gave
rise to overshoots in measured egg output after MDA ceased
Figure 1. Dynamics of protective antibody and egg output during and after treatment, by immune decay rate. Results are shown for
the situation where there is no reduction in transmission. Treatment was applied at yearly intervals for 5 years to school-aged children (6–15 years
old) with 75% coverage. Treatment was applied the day after surveys marked *. (a) Antibody levels and (b) egg output are shown relative to pre-
treatment levels for selected parameter sets which reproduced cross-sectional and post-treatment patterns in previous analyses. Results are shown
separately for parameter sets with different rates of immune decay: 0.008, 0.08 and 0.8 year21; for all parameter sets, worm life span is 6.5 years.
doi:10.1371/journal.pntd.0003059.g001
Figure 2. Dynamics of protective antibody and egg output during and after treatment, by worm life span. Results are shown for the
situation where there is no reduction in transmission. Treatment was applied at yearly intervals for 5 years to school-aged children (6–15 years old)
with 75% coverage. Treatment was applied the day after surveys marked *. (a) Antibody levels and (b) egg output are shown relative to pre-treatment
levels for selected parameter sets which reproduced cross-sectional and post-treatment patterns in previous analyses. Results are shown separately
for parameter sets with different mean parasite life span: 3, 6.5 and 10 years; for all parameter sets, the immune decay rate is 0.8 year21.
doi:10.1371/journal.pntd.0003059.g002
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(figure 3). The overshoots were identified by eye from plots, but
were found to correspond to particular parameter values. For
models without an antigen threshold, all of these parameter
combinations had rapid immune decay (0.8 year21); for models
with an antigen threshold, the parameter combinations all had
rapid immune decay (0.8 year21), a low antigen threshold (25
antigen units) and moderate antibody strength (0.256 units per
plasma cell). Of all the unique parameter sets explored, 11/293
parameter sets for models including an antigen threshold, and 4/
12 without an antigen threshold, gave rise to an infection
overshoot. Models without an antigen threshold predicted higher
overshoots (.70% above pre-treatment levels) than models which
included an antigen threshold (where overshoots were around 14–
23%; figure 3).
Treatment schedules 2 to 4 varying treatment frequency,
coverage and targeting
The impacts of separately varying the frequency of treatment
and the coverage and age-range of the target population
(treatment schedules 2–4) are shown for single parameter
combinations (figure 4), but demonstrate trends seen for all
parameter sets. Results are shown for one parameter set that did
and one that did not give an overshoot in egg output for treatment
schedule 1.
With biennial treatment (schedule 2), protective antibody
declined and egg output increased following non-treatment years,
but their levels approached those seen with annual treatment
(schedule 1) one year after each treatment (figure 4). The
overshoot in egg output was less pronounced for biennial versus
yearly treatment (figure 4d). Changing the level of coverage of the
school-aged population (90% coverage (schedule 3) vs.75%
(schedule 1)) made little difference; it gave a slightly greater
increase in antibody and greater reduction in egg output during
treatment, and a slightly more pronounced overshoot in egg
output (figure 4). Treating both adults and children (aged 6–34
years old, schedule 4) rather than just school-aged children (6–15
years old, schedule 1) gave a much larger antibody boost and
greater reduction in egg output during the treatment programme
and greater overshoot in egg output (figure 4).
Treatment schedules 5 and 6 – Reduction of transmission
The effects of assuming that transmission is reduced during
MDA are shown for one parameter set (figure 5), but these trends
were seen for all of the parameter sets examined. If 100%
reduction in (i.e. no) transmission was assumed during MDA
(schedule 5), protective antibody always fell below pre-treatment
levels at some point, before treatment ceased if there was rapid
immune decay (0.8 year21; figure 5a). Egg output was always
reduced to below 5% of pre-treatment levels after five treatment
rounds and overshoots in egg output were always predicted
(figure 5b). Higher infection rates gave rise to higher and earlier
overshoots in egg output (data not shown). With 50% transmission
reduction (schedule 6), antibody levels always dropped below pre-
treatment levels, but more slowly and to a lesser extent than when
100% reduction in transmission was assumed (figure 5a), and for
most parameter sets, egg output was still predicted to overshoot
pre-treatment levels, to a lesser extent than with 100% reduction
in transmission (figure 5b).
Discussion
Several MDA programs for schistosomiasis are currently
underway in Africa [41]. While their immediate impact on
infection and morbidity in affected individuals is unequivocal, their
long-term effects on infection dynamics are not yet fully
understood. Our models predict that population levels of S.
haematobium infection will be substantially reduced by repeated
MDA, while levels of protective antibody will be initially boosted
by treatment, in agreement with patterns seen in the field. We
predict that, in the long-term, levels of antibody could fall below
pre-treatment levels after or even during MDA. More rapid
declines in protective antibody levels are predicted with more
rapid immune decay, shorter worm life span or reduced
transmission. After the initial increased exposure to dying worms
that treatment brings about, the reduced worm burden leads to a
subsequent reduction in exposure to dying worms, leaving
antibody levels strongly influenced by immune decay rates.
Reduced transmission further reduces antigen exposure. Baseline
antigenic exposure rates are expected to be lower in models with a
longer worm life span, and so the reduced antigenic exposure
following treatment will have a more rapid effect in models with
short worm life span, leading to more rapid declines in antibody.
We found that measured egg output could rebound to levels
exceeding pre-treatment levels after cessation of MDA. Our
finding that this was very likely to happen if treatment temporarily
reduced transmission confirms findings from earlier work using
different models [10]. Importantly, we found that it could also
occur in the absence of any reduction in transmission, and was
more likely to occur if the immune response decayed rapidly. The
fact that, without reduced transmission, a rebound in infection
only happened for a restricted set of parameters, highlights how
important it is to estimate these parameters to improve the
accuracy of model predictions. The rate of decay of protective
immunity is particularly important. Some studies (mainly on S.
mansoni) suggest that schistosome-specific antibody levels may
Figure 3. Dynamics of egg output during and after treatment
when an overshoot in egg output occurs. Results are shown for
the situation where there is no reduction in transmission, individually
for only those parameter combinations where an overshoot in egg
output levels is seen after treatment stops. Results are distinguished for
models which include an antigen threshold (solid lines; n = 11) and
models which do not (dot-dashed lines; n = 4). The shaded area shows
the 95% credible interval for all parameter sets in which no overshoot in
egg output is seen (n = 290). For all parameter sets, the immune decay
rate is 0.8 year21. For models including an antigen threshold, antibody
strength is 0.256 per plasma cell and the antigen threshold is 25 antigen
units.
doi:10.1371/journal.pntd.0003059.g003
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decline below pre-treatment levels following an initial boost,
behaviour predicted for medium- or short-lived antibody respons-
es in our model [42,43], but this is not always seen and more
accurate estimates are required.
Our results suggests that MDA might disrupt the build-up of
protective immunity (or may disrupt existing immunity) against
schistosomes, despite short-term boosting of this protective
response. Interestingly, a reduction in antibody levels below pre-
treatment levels during MDA did not necessarily correspond with
overshooting of egg output after treatment ceased. It should be
noted that, even when overshoots in egg output occur after
treatment stops, the overall impact of the intervention on egg
output (taking the overshoots into account) may still be positive;
the reductions in egg output during the control programme may
be sufficient to offset the increases seen after treatment stops.
We found that increasing the coverage of treatment of school
children from 75% to 90% only increased population antibody
levels and decreased measured infection levels by a very small
amount. The random allocation of treatment at each round meant
that even at 75% coverage, the chances of an individual never
being treated over the five rounds of treatment were very small,
which may account for the comparatively small coverage effect.
Two previous modelling studies looking at S. haematobium in
Ghana [8] and S. japonicum in China [44] also found little
difference in long-term infection dynamics between biennial and
annual treatment. However, other modelling studies have
Figure 4. Dynamics of protective antibody and egg output under different treatment regimes. Results are shown for the situation where
there is no reduction in transmission. Results are shown for (a,c) antibody and (b,d) egg output, for two different parameter combinations. Treatment
was applied over a five-year period, with treatment frequency, coverage and targeting in the following combinations: blue diamonds - standard;
yellow squares - biennial treatment; pink triangles - 90% coverage; green circles - treatment of 6–34 year olds. Treatment was applied the day after
surveys marked * for all except biennial treatment, where treatment was applied the day after surveys 0, 2 and 4.
doi:10.1371/journal.pntd.0003059.g004
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suggested different impacts of biennial versus annual treatment
[9,45]. Treating the whole population rather than just school-aged
children gave amore pronounced boost to population-level protective
antibody and a greater reduction in egg output during MDA, but
meant that any overshooting of egg output after treatment ceased
became more pronounced, suggesting that infection rebounds could
be more serious following more intensive control efforts.
Previous modelling studies which considered the effects of
acquired immunity on the impact of MDA suggest that the
strength and duration of protective immune responses play an
important role in determining infection dynamics [10], which was
also found here. Our results suggest that, without any reduction in
transmission post-treatment, an overshoot in measured infection
levels after treatment stops is most likely to occur with relatively
rapid immune decay rates (half-life of 10 months); in contrast,
Chan et al. (1996) [10] reported overshoots with slow immune
decay rates (half-life of 7 years), and not with more rapid decay.
This discrepancy may arise because they compensated for slow
immune decay rates with higher infection rates [10]. In the current
analysis, when treatment was assumed to reduce transmission,
higher infection rates gave rise to more pronounced overshoots in
egg output.
Our results support the long-term maintenance and monitoring
of existing MDA programmes, to ensure that treatment continues
while transmission is still ongoing. In addition to MDA, other
measures to reduce transmission should also be strengthened,
including the provision of safe water and sanitation facilities, and
good health education [46–48].
In conclusion, our models predict that, with protective immune
responses stimulated by dying S. haematobium worms, repeated
MDA will boost protective immunity initially, but antibody levels
could decline below pre-treatment levels during or after MDA. In
some circumstances, we also predict that post-MDA egg output
could exceed pre-intervention levels. Field data are not currently
available to test these predictions, but they have been made using a
calibrated model which reproduces robust patterns seen in short-
term pre- and post-treatment studies of S. haematobium infection
[28]. While MDA programmes have had substantial impact upon
schistosomiasis infection levels, this analysis highlights the potential
negative consequences of ceasing a mass treatment programme.
Supporting Information
Figure S1 Dynamics of protective antibody and egg
output during and after treatment, by immune decay
rate: Absolute values. The results from figure 1 are shown
using absolute, rather than relative, values. (a) Antibody levels and
(b) egg output are shown for selected parameter sets with different
rates of immune decay: 0.008, 0.08 and 0.8 year21; for all
parameter sets, worm life span is 6.5 years.
(TIF)
Figure S2 Dynamics of protective antibody and egg
output during and after treatment, by worm life span,
for different immune decay rates. Similar results to figure 2
are shown for lower immune decay rates. (a,c) Antibody levels and
(b,d) egg output are shown relative to pre-treatment levels for
selected parameter sets which reproduced cross-sectional and post-
treatment patterns in previous analyses. Results are shown
separately for parameter sets with different mean parasite life
span: 3, 6.5 and 10 years; the immune decay rate is (a,b) 0.08
year21, (c,d) 0.008 year21.
(TIF)
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Figure 5. Dynamics of protective antibody and egg output during and after treatment, for different transmission assumptions.
Treatment was applied at yearly intervals for 5 years to school-aged children (6–15 years old) with 75% coverage. Treatment was applied the day after
surveys marked *. (a) Antibody levels and (b) egg output are shown relative to pre-treatment levels for one selected parameter set which reproduced
cross-sectional and post-treatment patterns in previous analyses. Results are shown with 0, 50 or 100% transmission reduction assumed during MDA
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